CA2466032A1 - Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques - Google Patents

Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques Download PDF

Info

Publication number
CA2466032A1
CA2466032A1 CA002466032A CA2466032A CA2466032A1 CA 2466032 A1 CA2466032 A1 CA 2466032A1 CA 002466032 A CA002466032 A CA 002466032A CA 2466032 A CA2466032 A CA 2466032A CA 2466032 A1 CA2466032 A1 CA 2466032A1
Authority
CA
Canada
Prior art keywords
dosage form
controlled
solid
agent
pharmaceutical dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466032A
Other languages
English (en)
Inventor
Laure Patricia Ouadji Njiki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Labopharm Barbados Ltd
Labopharm Inc
Paladin Labs Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Barbados Ltd, Labopharm Inc, Paladin Labs Europe Ltd filed Critical Labopharm Barbados Ltd
Publication of CA2466032A1 publication Critical patent/CA2466032A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention se rapporte à des formes posologiques à libération contrôlée destinées à une administration orale. Cette forme posologique comprend un agent thérapeutique qui est métabolisé dans le tractus gastro-intestinal supérieur en combinaison à un agent à libération contrôlée de manière à être hydrodynamiquement équilibrée afin que, lors du contact avec le fluide gastrique, ladite forme posologique possède une densité apparente inférieure à 1 g/ml et par conséquent s'avère susceptible de flotter dans le fluide gastrique. Cette forme posologique est retenue dans l'estomac pendant le laps de temps lui permettant de libérer sensiblement tous les médicaments qu'elle contient. En outre, cette forme posologique permet une libération du médicament pendant un laps de temps prolongé de sorte que l'administration de l'agent thérapeutique à l'intestin grêle se déroule de manière régulière plutôt que subite. Cette libération régulière dans le temps de l'agent thérapeutique au niveau du site de métabolisation et d'absorption permet d'empêcher une saturation enzymatique et favorise par conséquent une meilleure biodisponibilté de l'agent thérapeutique.
CA002466032A 2001-10-29 2002-10-29 Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques Abandoned CA2466032A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01125761.5 2001-10-29
EP01125761 2001-10-29
PCT/EP2002/012062 WO2003037296A2 (fr) 2001-10-29 2002-10-29 Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques

Publications (1)

Publication Number Publication Date
CA2466032A1 true CA2466032A1 (fr) 2003-05-08

Family

ID=8179102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466032A Abandoned CA2466032A1 (fr) 2001-10-29 2002-10-29 Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques

Country Status (6)

Country Link
EP (1) EP1439820A2 (fr)
JP (1) JP2005509643A (fr)
AU (1) AU2002351798A1 (fr)
CA (1) CA2466032A1 (fr)
MX (1) MXPA04004035A (fr)
WO (1) WO2003037296A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048219A3 (fr) * 2005-09-09 2007-07-19 Labopharm Inc Composition medicamenteuse a liberation prolongee
US7988998B2 (en) 2002-10-25 2011-08-02 Labopharm Inc. Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5355002B2 (ja) 2008-09-10 2013-11-27 オリンパスメディカルシステムズ株式会社 浮き量合否判定システム、浮き量合否判定用表示システム、浮き量合否判定方法および浮き量合否判定用表示方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
EP1281397A1 (fr) * 1998-09-14 2003-02-05 Ranbaxy Laboratories Limited Système d' apport médicamenteux régulé administré oralement pour une régulation spatiale et temporelle
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
AU2001232020A1 (en) * 2000-02-09 2001-08-20 West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited Floating drug delivery composition

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7988998B2 (en) 2002-10-25 2011-08-02 Labopharm Inc. Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
WO2007048219A3 (fr) * 2005-09-09 2007-07-19 Labopharm Inc Composition medicamenteuse a liberation prolongee
US7829120B2 (en) 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US9439866B2 (en) 2005-09-09 2016-09-13 Angelini Pharma, Inc. Trazodone composition for once a day administration

Also Published As

Publication number Publication date
EP1439820A2 (fr) 2004-07-28
AU2002351798A1 (en) 2003-05-12
MXPA04004035A (es) 2004-10-29
JP2005509643A (ja) 2005-04-14
WO2003037296A3 (fr) 2003-12-24
WO2003037296A2 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
Singh et al. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention
AU608208B2 (en) Therapeutic agents
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
Kotreka et al. Gastroretentive floating drug-delivery systems: a critical review
Gopalakrishnan et al. Floating drug delivery systems: A Review
AU774957B2 (en) Hydrodynamically balancing oral drug delivery system
ES2200166T3 (es) Comprimido farmaceutico de liberacion controlada que contiene un soporte a base de amilosa reticulada e hidroxipropilmetilcelulosa.
CA2412490A1 (fr) Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
AU2001268722A1 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1509208A1 (fr) Equilibrage hydrodynamique de systeme de delivrance de medicaments administres oralement, par liberation biphasique
EA012377B1 (ru) Твёрдые пероральные фармацевтические композиции для введения один раз в сутки, содержащие прегабалин, матрицеобразующий агент и агент набухания
US20020119192A1 (en) Controlled release formulations for oral administration
Bhosale et al. A comprehensive review on floating drug delivery system (FDDS)
CA2466032A1 (fr) Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques
US20030138486A1 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
Bhoyar et al. An overview of a gastro retentive floating drug delivery system
Radha Krishna Formulation and evaluation of floating drug delivery system of amoxicillin trihydrate
Sabale et al. Formulation and Evaluation of Floating Dosage Forms: An Overview.
Katakam et al. Floating drug delivery systems: a review
Kumar et al. A systematic review on floating drug delivery system
Honkanen Biopharmaceutical evaluation of orally and rectally administered hard hydroxypropyl methylcellulose capsules
Mercy et al. FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING IN-SITU GEL OF MINOCYCLINE HCL
Tutunji Development of a gastroretentive controlled release metformin delivery system
Rao et al. A CONCISE REVIEW ON FLOATING DRUG DELIVERY SYSTEM

Legal Events

Date Code Title Description
FZDE Dead